When it comes to life-threatening diseases, we are one family. We at Kiadis are focusing our research & development on NK cell therapeutics, leveraging the natural strengths of our immune systems to source the best cells for life.
Location: Netherlands, North Holland, Amsterdam
Founded date: 1997
Investors 2
| Date | Name | Website |
| - | Draper Esp... | draperespr... |
| - | Life Scien... | lspvc.com |
Mentions in press and media 15
| Date | Title | Description |
| 25.07.2024 | Syngene Q1 net profit down 19% to ₹75.7 crore | Syngene International Limited, the contract research unit of Biocon, has reported a dip of 19 per cent year-on-year (Y-o-Y) in profit after tax (PAT) from ₹93.4 crore to ₹75.7 crore in the first quarter that ended June 30, 2024. Also read: ... |
| 14.05.2021 | KIADIS PHARMA N.V. Kiadis Pharma N : - Notice of Annual General Meeting of Shareholders | Amsterdam, The Netherlands - Kiadis Pharma N.V. ('Kiadis Pharma' or the 'Company') (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, announces that its Annual General Meeting of shareholders ('AGM') will be... |
| 13.05.2021 | Notice of Annual General Meeting of Shareholders | Amsterdam, The Netherlands, 13 May 2021 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that its Annual General Meeting of sharehold... |
| 13.04.2021 | Sanofi declares the Offer for Kiadis unconditional | This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 16, paragraph 1 and 2 and Article 17 paragraph 1 of the Netherla... |
| 09.04.2021 | Kiadis employee options committed under the Sanofi Offer | This is a press release by Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Section 5 paragraphs 4 and 5 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the “Decree”) in connection with the public o... |
| 07.04.2021 | Kiadis Pharma announces annual results for the year ended December 31, 2020 | New strategic focus results in significant progress in cell based therapies Amsterdam, The Netherlands, April 7, 2021 – Kiadis Pharma N.V. (“Kiadis”, “Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage... |
| 30.03.2021 | Kiadis EGM adopts all resolutions related to the recommended public offer by Sanofi | This is a press release by Kiadis Pharma N.V. (“Kiadis”) in connection with the public offer by Sanofi Foreign Participations B.V. (“the Offeror”), a wholly owned subsidiary of Sanofi (“Sanofi”), for all the issued and outstanding ordinary ... |
| 15.02.2021 | Kiadis issues shares to Kreos Capital following agreed conversion of convertible bonds | This is a press release by Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Section 5 paragraphs 4 and 5 and Section 6 paragraph 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the “Decree”) in co... |
| 12.02.2021 | Sanofi launches recommended cash offer for all shares in Kiadis | This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 4 paragraph 1, Article 10 paragraph 1 and 3, and Article 18 para... |
| 30.09.2020 | KIADIS PHARMA N.V. Kiadis Pharma N : announces results for the six months ended June 30, 2020 and significant progress made to date in 2020 in all development programs | K-NK002 (HSCT): IND approved to enter Phase 2 development K-NK003 (AML R/R): IND approved and multiple patients enrolled for Phase 1 investigator initiated trial for treatment of relapsed/refractory acute myeloid leukemia (R/R AML) K-NK004 ... |
Show more